Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology

Experimental Physiology

Volumn 96, Issue 9, 2011, Pages 863-874

  Qi, Yanfei ^a   Shenoy, Vinayak ^a   Wong, Fong ^a   Li, Hongwei ^b   Afzal, Aqeela ^a   Mocco, J ^a   Sumners, Colin ^a   Raizada, Mohan K ^a   Katovich, Michael J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN (1-7); ANGIOTENSIN CONVERTING ENZYME 2; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 10; INTERLEUKIN 6; LENTIVIRUS VECTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HYPOXIA; IN VITRO STUDY; ISCHEMIA; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; RAT; VIRAL GENE DELIVERY SYSTEM;

EID: 80051949470     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2011.056994     Document Type: Article

References (48)

1. Al-Maghrebi M, Benter IF & Diz DI (2009). Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59, 263-268.
2. Averill DB, Ishiyama Y, Chappell MC & Ferrario CM (2003). Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108, 2141-2146.
3. Boffa GM, Zaninotto M, Sartor R, Mion M, Berton A, Pasqualetto C, Razzolini R & Plebani M (2009). Interleukin-6 and tumor necrosis factor-α as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. J Cardiovasc Med (Hagerstown) 10, 758-764.
4. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME & Johnston CI (2005). Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26, 369-375; discussion 322-4.
5. 2 receptors in the mouse heart. Hypertension 46, 937-942.
6. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ, Semple-Rowland SL & Raizada MK (2003). Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 12, 221-228.
7. De Mello WC (2004). Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 5, 203-208.
8. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ & Raizada MK (2008). Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51, 712-718.
9. Diez-Freire C, Vazquez J, Correa de Adjounian MF, Ferrari MFR, Yuan L, Silver X, Torres R & Raizada MK (2006). ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27, 12-19.
10. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB & Diz DI (1997). Counterregulatory actions of angiotensin-(1-7). Hypertension 30, 535-541.
11. Ferreira AJ, Castro CH, Guatimosim S, Almeida PW, Gomes ER, Dias-Peixoto MF, Alves MN, Fagundes-Moura CR, Rentzsch B, Gava E, Almeida AP, Guimarães AM, Kitten GT, Reudelhuber T, Bader M & Santos RA (2010). Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther Adv Cardiovasc Dis 4, 83-96.
12. Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GA, Almeida AP, Caliari MV & Santos RA (2007). The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 292, H1113-H1119.
13. Ferreira AJ, Santos RA & Almeida AP (2001). Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38, 665-668.
14. Ferreira AJ, Shenoy V, Yamazato Y, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh P, Katovich MJ & Raizada MK (2009). Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179, 1048-1054.
15. Giani JF, Munoz MC, Mayer MA, Veiras MA, Arranz C, Taira CA, Turyn D, Toblli JE & Dominici FP (2010). Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am J Physiol Heart Circ Physiol 298, H1003-H1013.
16. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK & Katovich MJ (2007a). ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113, 357-364.
17. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK & Katovich MJ (2007b). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292, H736-H742.
18. Grobe JL, Mecca AP, Mao H & Katovich MJ (2006). Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290, H2417-H2423.
19. Gurzu B, Costuleanu M, Slatineanu SM, Ciobanu A & Petrescu G (2005). Are multiple angiotensin receptor types involved in angiotensin (1-7) actions on isolated rat portal vein? J Renin Angiotensin Aldosterone Syst 6, 90-95.
20. 2 angiotensin receptor gene expression in human heart failure. Circulation 95, 1201-1206.
21. Heitsch H, Brovkovych S, Malinski T & Wiemer G (2001). Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37, 72-76.
22. Iusuf D, Henning RH, van Gilst WH & Roks AJ (2008). Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585, 303-312.
23. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T & Steckelings UM (2008). Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118, 2523-2532.
24. Keidar S, Kaplan M & Gamliel-Lazarovich A (2007). ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res 73, 463-469.
25. Kim MA, Yang D, Kida K, Molotkova N, Yeo SJ, Varki N, Iwata M, Dalton ND, Peterson KL, Siems WE, Walther T, Cowling RT, Kjekshus J & Greenberg B (2010). Effects of ACE2 inhibition in the post-myocardial infarction heart. J Card Fail 16, 777-785.
26. Kono T, Taniguchi A, Imura H, Oseko F & Khosla MC (1986). Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man. Life Sci 38, 1515-1519.
27. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F & van Gilst WH (2002). Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105, 1548-1550.
28. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM & Reudelhuber TL (2008). Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103, 1319-1326.
29. Methot D, vanKats JP, Lochard N, Tremblay F, Silversides DW & Reudelhuber TL (2001). Development and application of a biological peptide pump for the study of the in vivo actions of angiotensin peptides. Am J Hypertens 14, 38S-43S.
30. Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M, Oshima T & Kambe M (2003). Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41, 814-818.
31. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M & Oshima T (2006). AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci 80, 82-88.
32. Qi Y, Liu X, Li H, Shenoy V, Li Q, Hauswirth WW, Sumners C & Katovich MJ (2010). Selective tropism of the recombinant adeno-associated virus 9 serotype for rat cardiac tissue. J Gene Med 12, 22-34.
33. Rodgers KE, Ellefson DD, Espinoza T, Hsu YH, diZerega GS & Mehrian-Shai R (2006). Expression of intracellular filament, collagen, and collagenase genes in diabetic and normal skin after injury. Wound Repair Regen 14, 298-305.
34. Sampaio WO, Nascimento AA & Santos RA (2003). Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284, H1985-H1994.
35. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL & Bader M (2004). Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17, 292-299.
36. 7-angiotensin-(1-7). Hypertension 41, 737-743.
37. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK & Katovich MJ (2010). The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182, 1065-1072.
38. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA & Lemos VS (2007). Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28, 702-707.
39. Steckelings UM, Henz BM, Wiehstutz S, Unger T & Artuc M (2005). Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol 153, 887-893.
40. Stumpf C, Seybold K, Petzi S, Wasmeier G, Raaz D, Yilmaz A, Anger T, Daniel WG & Garlichs CD (2008). Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail 10, 733-739.
41. Tallant EA, Ferrario CM & Gallagher PE (2005). Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289, H1560-H1566.
42. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW & LeJemtel TH (1996). Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28, 964-971.
43. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB & Mann DL (1996). Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27, 1201-1206.
44. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M & Kinoshita M (1998). Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31, 391-398.
45. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F, Schoemaker RG, Reudelhuber TL, van Gilst WH, Schultheiss HP, Tschöpe & Walther T (2010). Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail 3, 286-293.
46. Wiemer G, Dobrucki LW, Louka FR, Malinski T & Heitsch H (2002). AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40, 847-852.
47. Yamada K, Iyer SN, Chappell MC, Ganten D & Ferrario CM (1998). Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 32, 496-502.
48. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR & Canver CC (2003). Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108, 1707-1712.